tDCS for Preventing Falls in Elderly
Trial Summary
Do I need to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you are using sedating medications or have changed medications in the past month. Also, you cannot use neuro-active drugs.
Will I have to stop taking my current medications?
The trial excludes participants who have changed their medication within the previous month or who use sedating medications regularly. If you are on such medications, you may need to stop or adjust them to participate.
What data supports the idea that tDCS for Preventing Falls in Elderly is an effective treatment?
The available research shows that tDCS can help improve balance and reduce the risk of falls in older adults. One study found that tDCS improved balance control, as seen in better performance on balance tests and reduced postural sway. Another study showed that tDCS helped improve postural stability, which is important for preventing falls. Additionally, a review of multiple studies confirmed that tDCS significantly improved balance in older adults compared to a control group. These findings suggest that tDCS is a promising treatment for reducing fall risk in the elderly.12345
What data supports the effectiveness of the treatment Personalized tDCS for preventing falls in elderly?
Research shows that transcranial direct current stimulation (tDCS) can improve balance and postural control in older adults, which are important for preventing falls. Studies found that tDCS can enhance balance control, reduce postural sway, and improve dual-task walking, suggesting it may help reduce fall risk in the elderly.12345
What safety data exists for tDCS in preventing falls in the elderly?
The safety of transcranial direct current stimulation (tDCS) has been extensively reviewed. A 2016 evidence-based update on tDCS safety found no reports of serious adverse effects or irreversible injury across over 33,200 sessions and 1,000 subjects, including potentially vulnerable populations like the elderly. Conventional tDCS protocols used in human trials (up to 40 minutes, 4 milliamperes, and 7.2 Coulombs) are considered safe. This suggests that tDCS is a well-tolerated and safe technique for use in older adults.12467
Is transcranial direct current stimulation (tDCS) safe for use in humans, including older adults?
Transcranial direct current stimulation (tDCS) is generally considered safe for humans, including older adults, with no reports of serious adverse effects or irreversible injury in over 33,200 sessions across various studies. It is a non-invasive and well-tolerated technique, even in potentially vulnerable populations like the elderly.12467
Is the treatment tDCS promising for preventing falls in elderly people?
How does the treatment tDCS for preventing falls in elderly differ from other treatments?
tDCS (Transcranial Direct Current Stimulation) is unique because it is a non-invasive brain stimulation technique that can improve balance and cognitive-motor function in older adults, potentially reducing fall risk. Unlike other treatments, it involves applying a mild electrical current to specific brain areas to enhance brain activity, which may improve dual-task performance and postural control.12346
What is the purpose of this trial?
The objective of this study is to determine if a four-week, 20-session intervention of personalized transcranial direct current stimulation (tDCS), as compared to sham intervention, improves dual task standing and walking performance (Aim 1), as well as other physical (Aim 2) and cognitive (Aim 3) factors on the causal pathway to falls, in older adults who report two or more falls within the past year and fear of falling again in the future, yet who do not have any acute or over neurological or musculoskeletal condition.Primary endpoints will include the "dual task" costs to gait speed when walking and postural sway speed when standing, as induced by performing a serial subtraction cognitive task (i.e., \[(speeddual task - speedsingle task) / speedsingle task) X 100\] (Aim 1), the Short Physical Performance Battery (Aim 2), and the Trail Making Test (Part B minus Part A) (AIM 3). Secondary endpoints will include the dual task cost to serial subtraction performance, additional gait and balance outcomes derived from the dual task paradigm, the Timed Up-and-Go, fear of falling, habitual physical activity, and performance within a battery of neuropsychological tests focused on global cognitive function, attention, verbal fluency and memory.
Research Team
Brad Manor, PhD
Principal Investigator
Hebrew SeniorLife
Eligibility Criteria
This trial is for adults aged 60 or older who have fallen twice in the past year, are worried about falling again, and have mobility and balance issues. They must score below a certain level on physical performance tests but can't join if they've had recent heart attacks, active cancer treatments, severe mental health conditions, blindness, contraindications to MRI or tDCS like seizures or metal implants, dementia, sedative use changes recently, inability to stand/walk unassisted for a minute.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive personalized tDCS intervention targeting the left dlPFC over a 4-week period
Follow-up
Participants are monitored for changes in cognitive and physical function post-intervention
Treatment Details
Interventions
- Personalized tDCS
Personalized tDCS is already approved in United States, European Union for the following indications:
- Depression
- Cognitive Impairment
- Auditory Hallucinations
- Rehabilitation for Stroke and Neurological Disorders
- Depression
- Cognitive Impairment
- Rehabilitation for Stroke and Neurological Disorders
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hebrew SeniorLife
Lead Sponsor